Entrada Therapeutics, INC Form 4 insider transactions

Kory James Wentworth, CFO of Entrada Therapeutics, sold shares of common stock between September 3rd and September 5th, 2024, to cover tax withholding obligations upon the vesting of restricted stock units.

Nathan Dowden, President & COO of Entrada Therapeutics, exercised stock options and sold shares of common stock on August 16, 2024, according to a Form 4 filing with the SEC.

Natarajan Sethuraman, Chief Scientific Officer of Entrada Therapeutics, sold a total of 1,238 shares of common stock on July 12 and July 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Entrada Therapeutics CEO Dipal Doshi sold shares of common stock on July 12 and July 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Kory James Wentworth, CFO of Entrada Therapeutics, sold 1,758 shares of common stock at a price of $14.95 on July 8, 2024, according to a Form 4 filing with the SEC.

Baker Bros. Advisors and affiliated entities purchased warrants to acquire Entrada Therapeutics common stock in a registered direct offering.

Director Kush Parmar acquired 16,000 stock options in Entrada Therapeutics, Inc. on June 13, 2024.

Director Peter S. Kim acquired 16,000 stock options in Entrada Therapeutics, Inc. on June 13, 2024.

Mary Thistle, a director at Entrada Therapeutics, acquired stock options for 16,000 shares of common stock on June 13, 2024.

Director Bernhardt G Zeiher of Entrada Therapeutics, Inc. acquired 16,000 stock options on June 13, 2024, exercisable at $16.45.

Director Gina Chapman acquired stock options for 16,000 shares of Entrada Therapeutics common stock on June 13, 2024.

Entrada Therapeutics CEO Dipal Doshi sold 1,000 shares of common stock on June 13, 2024, at a weighted average price of $16.1736, according to a Form 4 filing.

Director Peter S. Kim exercised stock options of Entrada Therapeutics, Inc. on June 3, 2024, acquiring 11,918 shares at $6.06 per share.

Natarajan Sethuraman, Chief Scientific Officer of Entrada Therapeutics, sold shares of common stock over three days in May under a pre-arranged 10b5-1 trading plan.

Entrada Therapeutics CEO Dipal Doshi sold a portion of his common stock holdings under a pre-arranged Rule 10b5-1 trading plan.

Director Peter S. Kim of Entrada Therapeutics, Inc. purchased 25,000 shares of common stock at an average price of $14.5869 on May 14, 2024.

Director Peter S. Kim of Entrada Therapeutics, Inc. [TRDA] recently purchased additional shares of common stock, increasing his beneficial ownership.

Director Peter S. Kim of Entrada Therapeutics, Inc. recently purchased 2,600 shares of common stock at an average price of $13.573 per share.

Director Peter S. Kim of Entrada Therapeutics, Inc. (TRDA) acquired 1,512 shares of common stock at a weighted average price of $13.7526 on March 28, 2024.

Director Peter S. Kim of Entrada Therapeutics, Inc. [TRDA] has been actively purchasing common stock, increasing his holdings over several transactions in March 2024.

Director Peter S. Kim of Entrada Therapeutics, Inc. [TRDA] reported the purchase of common stock over three days in March 2024.

Kory James Wentworth, CFO of Entrada Therapeutics, exercised options to acquire 9,000 shares of common stock at $2.10 per share on March 15, 2024.

Kory James Wentworth, CFO of Entrada Therapeutics, sold 4,086 shares of common stock at a weighted average price of $12.3067 on March 6, 2024, according to a Form 4 filing with the SEC.

Nathan Dowden, President & COO of Entrada Therapeutics, sold 1,826 shares of common stock at a weighted average price of $12.3213, executed under a pre-arranged 10b5-1 trading plan.

Entrada Therapeutics CEO Dipal Doshi reports acquisition of restricted stock units and stock options, along with sales to cover tax obligations.

Kory James Wentworth, CFO of Entrada Therapeutics, reports acquisition of restricted stock units and stock options, along with sales to cover tax obligations.

Nathan Dowden, President & COO of Entrada Therapeutics, reports the acquisition and disposal of common stock and stock options, including grants of restricted stock units and sales to cover tax obligations.

Natarajan Sethuraman, Chief Scientific Officer of Entrada Therapeutics, reports the acquisition of restricted stock units and stock options, along with sales of common stock to cover tax obligations.